Juventas Cell Therapy Ltd.
Clinical trials sponsored by Juventas Cell Therapy Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- CAR-T therapy takes on tough blood disorder in early trial Results expected Sep 2026 (estimated)
- New cell injection aims to tame Hard-to-Treat autoimmune nerve disorders Results expected Dec 2026 (estimated)
- Experimental cell therapy targets Hard-to-Treat nerve diseases Results expected Jun 2027 (estimated)
-
New cell injection aims to tame Hard-to-Treat autoimmune nerve disorders
Disease control Not yet recruitingThis early-stage study tests a new cell therapy called HY001N in 15 adults with relapsed or treatment-resistant autoimmune neurological diseases like neuromyelitis optica. The main goal is to check safety and side effects, while also looking for signs of improvement in disability…
Early phase 1 • Sponsor: Juventas Cell Therapy Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
CAR-T therapy takes on tough blood disorder in early trial
Disease control Not yet recruitingThis early-stage trial tests a new CAR-T cell therapy called inaticabtagene autoleucel for people with autoimmune hemolytic anemia (AIHA) that hasn't improved after at least three prior treatments. The study will enroll 12 adults and primarily check for safety and the right dose.…
Phase 1 • Sponsor: Juventas Cell Therapy Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC